Table 1.
Baseline recipient and donor characteristics in all patients and according to FSGS recurrence
| Baseline Characteristic | Overall Cohort (n=176) | No Recurrence (n=119) | Recurrence (n=57) |
|---|---|---|---|
| Follow-up, yr | 5.2 [3.0–8.1] | 6.2 [3.9–8.4] | 3.3 [1.6–5.9] |
| Age at transplantation, yr | 38 [29–47] | 38 [30–46] | 39 [28–49] |
| Age at diagnosis, yr | 27 [17–40] | 27 [17–36] | 29 [17–43] |
| Male sex | 106 (60) | 72 (61) | 34 (60) |
| Race/ethnicity | |||
| White | 98 (56) | 63 (53) | 35 (61) |
| Black | 19 (11) | 13 (11) | 6 (11) |
| Hispanic | 8 (5) | 6 (5) | 2 (4) |
| Asian | 8 (5) | 8 (7) | 0 (0) |
| Mixed | 18 (10) | 14 (12) | 4 (7) |
| Other/unknown | 25 (14) | 15 (13) | 10 (18) |
| BMI at transplantation | 25±5 | 26±5 | 24±5 |
| Manifestation of FSGS in native kidney | |||
| Nephrotic syndrome | 122 (69) | 78 (66) | 44 (77) |
| Unknown | 54 (31) | 41 (34) | 13 (23) |
| Time from diagnosis to ESKD, mo | 38 [14–75] | 40 [12–83] | 32 [15–62] |
| Time on dialysis, mo | 29 [11–57] | 29 [11–60] | 32 [12–51] |
| Type of dialysis | |||
| Hemodialysis | 127 (73) | 84 (71) | 43 (77) |
| Peritoneal dialysis | 21 (12) | 13 (11) | 8 (14) |
| Both | 15 (9) | 12 (10) | 3 (5) |
| Pre-emptive transplant | 12 (7) | 10 (8) | 2 (4) |
| Nephrectomy of native kidneys | 12 (7) | 4 (3) | 8 (14) |
| Prior transplant loss due to FSGS | 16 (9) | 6 (5) | 10 (18) |
| Number of prior transplants | |||
| None | 132 (75) | 89 (75) | 44 (75) |
| 1 | 39 (22) | 30 (25) | 9 (16) |
| 2 | 5 (3) | 0 (0) | 5 (9) |
| PRA>50% | 28 (18) | 20 (18) | 8 (17) |
| DSA at transplantation | 14 (9) | 10 (9) | 4 (8) |
| Deceased donor | 118 (67) | 82 (69) | 36 (63) |
| Extended criteria donor (KDPI>85%) | 16 (14) | 12 (15) | 4 (12) |
| Cold ischemia time, h | 19±7.0 | 18.6±6.9 | 20.1±7.2 |
| Living donor | 58 (33) | 37 (31) | 21 (37) |
| Living related donor | 39 (67) | 22 (59) | 17 (81) |
| Donor age, yr | 40±14 | 40±15 | 40±14 |
| HLA-A/B/DR mismatch | 3.2±1.6 | 3.3±1.6 | 2.9±1.6 |
| Induction therapy | |||
| None | 22 (13) | 15 (13) | 7 (12) |
| Anti-thymocyte globulin | 72 (42) | 46 (40) | 26 (46) |
| Basiliximab | 73 (42) | 51 (44) | 22 (39) |
| Daclizumab | 6 (3) | 4 (3) | 2 (4) |
| Immunosuppressive regimen | |||
| Tacrolimus + MMF + steroids | 126 (72) | 85 (72) | 41 (72) |
| Cyclosporine + MMF + steroids | 29 (17) | 21 (18) | 8 (14) |
| Tacrolimus + MMF | 9 (5) | 5 (4) | 4 (7) |
| Other | 11 (6) | 7 (6) | 4 (7) |
| Prophylactic plasmapheresis | 22 (13) | 13 (11) | 9 (16) |
Values represent frequency (percentage), mean±SD, or median [interquartile range]. BMI, body mass index; PRA, panel reactive antibody; DSA, donor-specific antibody; KDPI, kidney donor profile index; MMF, mycophenolate mofetil.